BRAIN Biotech AG reported earnings results for the second quarter and six months ended March 31, 2022. For the second quarter, the company reported sales was EUR 13.09 million compared to EUR 9.92 million a year ago. Revenue was EUR 13.78 million compared to EUR 11.31 million a year ago. Net loss was EUR 1.6 million compared to net income of EUR 2.07 million a year ago. Basic loss per share from continuing operations was EUR 0.07 compared to basic earnings per share from continuing operations of EUR 0.1 a year ago. Diluted loss per share from continuing operations was EUR 0.07 compared to diluted earnings per share from continuing operations of EUR 0.1 a year ago.
For the six months, sales was EUR 23.27 million compared to EUR 18 million a year ago. Revenue was EUR 24.21 million compared to EUR 19.8 million a year ago. Net loss was EUR 3.96 million compared to EUR 1.29 million a year ago. Basic loss per share from continuing operations was EUR 0.18 compared to EUR 0.06 a year ago. Diluted loss per share from continuing operations was EUR 0.18 compared to EUR 0.06 a year ago.